Latest News from ASCO in Action

Latest News from ASCO in Action

November 25, 2014

The U.S. Food and Drug Administration has issued a notification that Mylan plans to discontinue production of Mesna 100 mg/mL, 10 mL MDV in the summer of 2015.

November 25, 2014

The U.S. Department of Health and Human Services issued a Notice of Proposed Rulemaking, which proposes regulations to implement reporting requirements for clinical trials that are subject to Title VIII of the Food and Drug Administration Amendments Act of 2007.

November 24, 2014

The current Congress is closer than any other Congress has been to repealing the fundamentally flawed sustainable growth rate (SGR) formula. But, time is running out. Due to unpredictable SGR estimates—which are currently at historic lows—the cost to repeal could go up at any time. And, if the SGR is not repealed in the current lame duck session, the next Congress will be forced to consider patches that would cost billions more.

ASCO's ACT Network

ASCO's ACT Network

ALERT CONGRESS TODAY! Use ASCO's ACT Network to contact your elected officials on important policy issues impacting cancer care. 

ASCO Issue Backgrounders

ASCO Issue Backgrounders

ASCO offers issue backgrounders to help provide an overview of the major policy issues that impact patients with cancer and the physicians who care for them. The issue backgrounders cover topics such as reimbursement, health equity, cancer research funding, and more.

Click here to read the backgrounds and help develop your understanding of cancer policy issues.

NIH Funding Educational Series

NIH Funding Educational Series

ASCO explores the decade-long decline in federal funding for cancer research – and why this decline must be reversed. Read more here.